Online citations, reference lists, and bibliographies.
← Back to Search

Peroxiredoxins In Colorectal Neoplasms.

X. Wu, Z. Fu, X. Wang
Published 2010 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Peroxiredoxins (Prxs) are novel group proteins with efficient antioxidant capacity, and some of them also have effects on cell proliferation, differentiation, apoptosis, and chemotherapy and radiotherapy resistance. Altogether six distinct Prxs expressions were investigated in histological samples of colorectal neoplasm and the distant normal tissues and investigated associatedly with parameters such as clinical stage and lymphnodes metastasis. Normal colorectal tissues were almost negative for Prxs, except Prx4 (15/32). In colorectal cancer tissues, the most prominent reactivity was observed with Prx2 in 23/32 cases, while the corresponding figures for others was 21/32 (Prx1), 18/32 (Prx3, Prx5, Prx6) and 8/32 (Prx4). Prx1 (P=0.023), Prx2 (P=0.012), and Prx5 (P=0.028) were the isoforms that showed significantly increased expression in colorectal cancer patients with stage III or lymphnodes metastasis-positive cases. There was a significant relationship between the expression of Prx1 and Prx2 (rs=0.425, P=0.015) and between Prx3 and Prx4 (rs=0.364, P=0.041). Additionally, 8 cases were studied by western analysis. Prx1, 2, 3, 5 and 6 were particularly elevated in tumors compared to nonmalignant tissue as assessed by immunohistochemistry. It appeared that some Prxs were upexpression in colorectal cancer tissues and may have some prognostic significance; the induction of Prxs could be explained by increased production of reactive oxygen species in carcinomatous tissue.
This paper references
10.1146/ANNUREV.PH.48.030186.003401
Antioxidant defenses in the lung.
I. Fridovich (1986)
10.1016/0140-6736(90)91889-I
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement
A. Ekbom (1990)
10.1111/J.1432-1033.1993.TB18025.X
Strategies of antioxidant defense
H. Sies (1993)
Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae.
H. Z. Chae (1993)
Cloning , sequencing , and mutation of thiolspecific antioxidant gene of Saccharomyces cerevisiae
Z. ChaeH. (1993)
10.1016/s0021-9258(17)42072-2
On the protective mechanism of the thiol-specific antioxidant enzyme against the oxidative damage of biomacromolecules.
M. B. Yim (1994)
10.1016/s0021-9258(18)47038-x
Thioredoxin-dependent peroxide reductase from yeast.
H. Z. Chae (1994)
Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation.
D. Y. Jin (1997)
10.1074/jbc.272.49.30952
Regulatory Role for a Novel Human Thioredoxin Peroxidase in NF-κB Activation*
D. Jin (1997)
10.1074/jbc.272.49.30615
Thioredoxin Peroxidase Is a Novel Inhibitor of Apoptosis with a Mechanism Distinct from That of Bcl-2*
Ping Zhang (1997)
10.1074/jbc.273.11.6303
Characterization of a Mammalian Peroxiredoxin That Contains One Conserved Cysteine*
S. W. Kang (1998)
10.1074/jbc.274.43.30451
Cloning and Characterization of AOEB166, a Novel Mammalian Antioxidant Enzyme of the Peroxiredoxin Family*
B. Knoops (1999)
10.1074/jbc.274.42.29897
Characterization of Human and Murine PMP20 Peroxisomal Proteins That Exhibit Antioxidant Activity in Vitro *
H. Yamashita (1999)
10.1016/S0304-3835(99)00243-8
Peroxiredoxin I expression in human thyroid tumors.
T. Yanagawa (1999)
10.1074/JBC.275.24.18266
Role of Peroxiredoxins in Regulating Intracellular Hydrogen Peroxide and Hydrogen Peroxide-induced Apoptosis in Thyroid Cells*
H. Kim (2000)
10.1046/J.1523-1747.2000.00177.X
Peroxiredoxin is ubiquitously expressed in rat skin: isotype-specific expression in the epidermis and hair follicle.
S. Lee (2000)
10.1016/S0304-3835(00)00434-1
Peroxiredoxin I expression in oral cancer: a potential new tumor marker.
T. Yanagawa (2000)
10.1074/jbc.M001943200
Identification of a New Type of Mammalian Peroxiredoxin That Forms an Intramolecular Disulfide as a Reaction Intermediate*
M. S. Seo (2000)
Antisense of human peroxiredoxin II enhances radiation-induced cell death.
S. Park (2000)
10.1006/BBRC.2001.5989
Augmented expression of peroxiredoxin I in lung cancer.
J. Chang (2001)
10.1038/emm.2002.38
Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death
Y. Yoo (2002)
10.1074/JBC.M106585200
Proteomics Analysis of Cellular Response to Oxidative Stress
T. Rabilloud (2002)
10.1002/path.1042
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma
V. Kinnula (2002)
10.1007/BF03402079
Nonredundant Antioxidant Defense by Multiple Two-Cysteine Peroxiredoxins in Human Prostate Cancer Cells
C. Shen (2002)
Peroxiredoxins in breast carcinoma.
P. Karihtala (2003)
10.1074/JBC.M307871200
Phorbol Ester-dependent Activation of Peroxiredoxin I Gene Expression via a Protein Kinase C, Ras, p38 Mitogen-activated Protein Kinase Signaling Pathway*
A. Hess (2003)
10.1016/S0891-5849(02)01167-X
Oxidative stress in viral and alcoholic hepatitis.
C. Loguercio (2003)
10.1158/0008-5472.CAN-04-3262
Protein Expression Profiles in Pancreatic Adenocarcinoma Compared with Normal Pancreatic Tissue and Tissue Affected by Pancreatitis as Detected by Two-Dimensional Gel Electrophoresis and Mass Spectrometry
Jianjun Shen (2004)
10.3727/0965040042380441
The differential proteome profile of stomach cancer: identification of the biomarker candidates.
J. S. Jang (2004)
10.1016/J.DRUP.2004.01.004
ROS stress in cancer cells and therapeutic implications.
H. Pelicano (2004)
10.1016/S1043-321X(05)80224-3
Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling
J. C. Chang (2005)
10.1016/J.CDP.2005.01.002
Identification of differentially expressed proteins during human urinary bladder cancer progression.
A. Memon (2005)
10.1002/PMIC.200401175
Comparative proteomic analysis of esophageal squamous cell carcinoma
Y. Qi (2005)
10.1016/J.FREERADBIOMED.2005.02.026
Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling.
S. Rhee (2005)
10.1002/ijc.21731
The global health burden of infection‐associated cancers in the year 2002
D. Parkin (2006)
10.1016/J.IJROBP.2005.10.012
Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression.
M. Chen (2006)
10.1089/ARS.2006.8.1003
Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis.
J. Nair (2006)
10.1002/ijc.23016
Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis
J. Lin (2007)
10.1021/pr7007237
Proteomic profiling of endothelial cells in human lung cancer.
Hye-jeong Park (2008)
10.1016/j.prp.2008.04.011
Oxidative stress in ulcerative colitis-associated carcinogenesis.
A. Roessner (2008)
10.1080/07357900802438577
Comparative Proteomic Analysis of Osteosarcoma Cell and Human Primary Cultured Osteoblastic Cell
X. Liu (2009)



This paper is referenced by
10.18632/aging.202784
The critical role of peroxiredoxin-2 in colon cancer stem cells
Linglong Peng (2021)
10.7150/jca.38057
Peroxiredoxins and Immune Infiltrations in Colon Adenocarcinoma: Their Negative Correlations and Clinical Significances, an In Silico Analysis
Xiuzhi Zhang (2020)
10.3390/antiox9111104
Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
E. Kim (2020)
10.1007/s12253-019-00783-1
Prdx2 Upregulation Promotes the Growth and Survival of Gastric Cancer Cells
Shouru Zhang (2019)
10.1134/S0006297919020019
Catalytic and Signaling Role of Peroxiredoxins in Carcinogenesis
M. Sharapov (2019)
10.3390/antiox7100136
Peroxiredoxins in Colorectal Cancer: Predictive Biomarkers of Radiation Response and Therapeutic Targets to Increase Radiation Sensitivity?
J. Fischer (2018)
10.1042/BSR20180667
The prognostic values of the peroxiredoxins family in ovarian cancer
(2018)
10.3390/cancers10090305
Peroxiredoxin II Regulates Cancer Stem Cells and Stemness-Associated Properties of Cancers
Nisansala Chandimali (2018)
10.1089/ars.2017.7422
Peroxiredoxin Involvement in the Initiation and Progression of Human Cancer.
M. Hampton (2017)
10.1042/BSR20160447
Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway
Jun Xu (2017)
10.18632/oncotarget.14801
Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients
Linglong Peng (2017)
10.1016/j.jprot.2016.03.050
The application of proteomics in different aspects of hepatocellular carcinoma research.
Xiaohua Xing (2016)
10.18632/oncotarget.13559
Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer
Rong Wang (2016)
Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.
J. Zhou (2015)
10.7314/APJCP.2015.16.4.1657
Plasma nuclear factor kappa B and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma.
S. Ismail (2015)
10.1007/s00432-015-1916-3
The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells
Lianqin Li (2015)
10.7314/APJCP.2014.15.7.2979
Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients.
L. Shi (2014)
10.1016/j.canlet.2013.10.002
Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/β-catenin signaling.
Weidong Lu (2014)
10.1371/journal.pone.0103185
Proteomic Characterization of Acyclovir-Induced Nephrotoxicity in a Mouse Model
Hong Lu (2014)
10.1186/1477-7819-11-173
Proteomic analysis of non-small cell lung cancer tissue interstitial fluids
Shaomin Li (2013)
10.1007/s11010-013-1891-4
Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress
Weidong Lu (2014)
10.1089/ars.2012.4599
Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.
E. Hanschmann (2013)
10.1007/s12094-013-1117-y
Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells
Y-G Wang (2014)
10.3892/OL.2012.648
Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer.
Seulhee Han (2012)
10.1016/j.humpath.2011.11.021
Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma.
Ponlapat Yonglitthipagon (2012)
10.3892/ijmm.2012.916
Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach.
B. Qiao (2012)
10.1371/journal.pone.0025056
Proteomic Analysis of Ovarian Cancer Proximal Fluids: Validation of Elevated Peroxiredoxin 1 in Patient Peripheral Circulation
E. Hoskins (2011)
Semantic Scholar Logo Some data provided by SemanticScholar